Related Experiment Video
Updated: Feb 26, 2026

Drug Treatment and In Vivo Imaging of Osteoblast-Osteoclast Interactions in a Medaka Fish Osteoporosis Model
Published on: January 1, 2017
Zoledronic acid for chronic kidney disease-associated osteoporosis
Sukanya Sakthivel1, Krista Dybtved Kjærgaard1, Per Ivarsen1,2
1Department of Renal Medicine, Aarhus University Hospital, Aarhus, Denmark.
Background:
Patients with chronic kidney disease have a high risk of fracture, but evidence-based treatment protocols for osteoporosis are lacking. Bisphosphonates are commonly used anti-resorptive drugs, but due to renal excretion, patients with chronic kidney disease have not been included in clinical trials.
Case Presentation:
We present a case of severe bone fragility in a patient on long-term hemodialysis therapy where zoledronate was well-tolerated and provided clinical improvement.
Conclusion:
This case highlights the potential role of bisphosphonates in chronic kidney disease-associated osteoporosis and the need for trials to establish the safety and efficacy of anti-resorptive drugs in this patient population.
Related Concept Videos
Chronic Kidney Disease IV: Nursing Management
Chronic Kidney Disease II: Clinical Manifestations
Chronic Kidney Disease I: Introduction
Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Acid Suppressive Drugs for Peptic Ulcer Disease: Antacids
However, this neutralization reaction between...
Chronic Kidney Disease III: Interprofessional Care
